Table 3.
Characteristics of patients evaluated for clinical trials by racial classification
| African-American, n = 713
|
White, n = 1242
|
Total, N = 1955
|
||
|---|---|---|---|---|
| n (%) | n (%) | N (%) | ||
| Gender | Women | 485 (68.0) | 844 (68.0) | 1329 (68.0) |
| Men | 228 (32.0) | 398 (32.0) | 626 (32.0) | |
| Age quartile | 21–48 years | 194 (27.2) | 280 (22.5) | 474 (24.2) |
| 49–57 years | 195 (27.3) | 319 (25.7) | 514 (26.3) | |
| 58–64 years | 166 (23.3) | 340 (27.4) | 506 (25.9) | |
| ≥65 years | 158 (22.2) | 303 (24.4) | 461 (23.6) | |
| Insurance | Private commercial | 230 (32.3) | 744 (59.9) | 974 (49.8) |
| Medicaid | 140 (19.6) | 79 (6.4) | 219 (11.2) | |
| Medicare | 229 (32.1) | 330 (26.6) | 559 (28.6) | |
| Uninsured | 114 (16.0) | 89 (7.2) | 203 (10.38) | |
| Cancer type | Solid tumor | 615 (86.2) | 983 (79.1) | 1598 (81.7) |
| Hematological | 82 (11.5) | 217 (17.5) | 299 (15.3) | |
| Missing | 16 (2.3) | 42 (3.4) | 58 (3.0) | |
| Trial phase | I | 58 (8.1) | 154 (12.4) | 212 (10.8) |
| II | 156 (21.9) | 262 (21.1) | 418 (21.4) | |
| III | 426 (59.7) | 678 (54.6) | 1104 (56.5) | |
| IV | 4 (0.6) | 10 (0.8) | 14 (0.7) | |
| None specifieda | 69 (9.7) | 138 (11.1) | 207 (10.6) | |
| Eligibility status | Eligible | 238 (33.4) | 504 (40.6) | 742 (37.9) |
| Ineligible | 341 (47.8) | 507 (40.8) | 848 (43.4) | |
| Not yet determined | 134 (18.8) | 231 (18.6) | 365 (18.7) | |
| Refusalsb | 130 (54.6) | 216 (42.8) | 346 (46.6) |
a
Patients considered for a generic set of studies (e.g., breast cancer) who were determined to be ineligible for any clinical trial.
b
All refusals are considered to be among eligible patients. Final eligibility determination may not have been completed for all refused patients as the workup stopped. Denominators for percentages are number eligible for that column.